{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-trial-of-inotuzumab-ozogamicin-nsc-772518-for-newly-diagnosed-high-risk-b-all-risk-adapted-post-induction-therapy-for-high-risk-b-all-mixed-phenotype-acute-leukemia-and-dis\/#breadcrumbitem"}]}